Details
Stereochemistry | ACHIRAL |
Molecular Formula | Al.3HO |
Molecular Weight | 78.0036 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[OH-].[Al+3]
InChI
InChIKey=WNROFYMDJYEPJX-UHFFFAOYSA-K
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Al |
Molecular Weight | 26.9815 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.rlsnet.ru/tn_index_id_12707.htmCurator's Comment: description was created based on several sources, including
https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434
Sources: https://www.rlsnet.ru/tn_index_id_12707.htm
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434
Algeldrate (Aluminium hydroxide) is the amphoteric inorganic compound used as an antacid in the treatment of Duodenal, Peptic and Stomach Ulcer and some other conditions. Aluminium hydroxide is preferred over other alternatives such as sodium bicarbonate because Al(OH)3, being insoluble, does not increase the pH of stomach above 7 and hence, does not trigger secretion of excess acid by the stomach. Brand names include Alu-Cap, Aludrox, Gaviscon or Pepsamar. It reacts with the excess acid in the stomach, reducing the acidity of the stomach content, which may relieve the symptoms of ulcers, heartburn or dyspepsia. Such products can cause constipation, because the aluminum ions inhibit the contractions of smooth muscle cells in the gastrointestinal tract, slowing peristalsis and lengthening the time needed for stool to pass through the colon. Some such products (such as Maalox) are formulated to minimize such effects through the inclusion of equal concentrations of magnesium hydroxide or magnesium carbonate, which have counterbalancing laxative effects. This compound is also used to control phosphate (phosphorus) levels in the blood of people suffering from kidney failure. Precipitated aluminum hydroxide is included as an adjuvant in some vaccines (e.g. anthrax vaccine). One of the well-known brands of aluminum hydroxide adjuvant is Alhydrogel, made by Brenntag Biosector. Since it absorbs protein well, it also functions to stabilize vaccines by preventing the proteins in the vaccine from precipitating or sticking to the walls of the container during storage. Aluminium hydroxide is sometimes mistakenly called "alum", which properly refers to aluminum potassium sulfate. Vaccine formulations containing aluminum hydroxide stimulate the immune system by inducing the release of uric acid, an immunological danger signal. This strongly attracts certain types of monocytes which differentiate into dendritic cells. The dendritic cells pick up the antigen, carry it to lymph nodes, and stimulate T cells and B cells. It appears to contribute to induction of a good Th2 response, so is useful for immunizing against pathogens that are blocked by antibodies. In the 1960s and 1970s, it was speculated that aluminum was related to various neurological disorders including Alzheimer's disease. Since then, multiple epidemiological studies have found no connection between exposure to aluminum and neurological disorders.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0002548 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18362170 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Alhydrogel Approved UseUnknown |
|||
Primary | Gelusil-Lac Approved UseUnknown |
|||
Primary | Gastracid Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[TNF-alpha secretion by human macrophage-like cells in response to wear particles and its modification by drugs]. | 1999 May |
|
Quartz exposure of the rat lung leads to a linear dose response in inflammation but not in oxidative DNA damage and mutagenicity. | 2001 Apr |
|
Effects of polyethylene and alpha-alumina particles on IL-6 expression and secretion in primary cultures of human osteoblastic cells. | 2002 Feb |
|
Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. | 2002 Nov |
|
The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation. | 2004 Aug |
|
Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics. | 2004 Jan 1 |
|
Comparison of the response of primary human blood monocytes and the U937 human monocytic cell line to two different sizes of alumina ceramic particles. | 2004 Jul |
|
Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. | 2005 May |
|
Large aqueous aluminum hydroxide molecules. | 2006 Jan |
|
Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling. | 2006 Mar |
|
Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays. | 2008 Feb |
|
Alumina nanoparticles induce expression of endothelial cell adhesion molecules. | 2008 May 30 |
|
Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. | 2009 Feb |
|
The effects of implant surface nanoscale features on osteoblast-specific gene expression. | 2009 Sep |
|
Inhibition of a protein tyrosine phosphatase using mesoporous oxides. | 2010 Mar 11 |
|
Aluminum nanoparticle exposure in L1 larvae results in more severe lethality toxicity than in L4 larvae or young adults by strengthening the formation of stress response and intestinal lipofuscin accumulation in nematodes. | 2011 Jan |
|
In vivo toxicity of nano-alumina on mice neurobehavioral profiles and the potential mechanisms. | 2011 Jan-Mar |
|
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
Al₂O₃ nanoparticles induce mitochondria-mediated cell death and upregulate the expression of signaling genes in human mesenchymal stem cells. | 2012 Nov |
|
Atomic layer deposition coating of carbon nanotubes with aluminum oxide alters pro-fibrogenic cytokine expression by human mononuclear phagocytes in vitro and reduces lung fibrosis in mice in vivo. | 2014 |
|
Toxicoproteomic analysis of pulmonary carbon nanotube exposure using LC-MS/MS. | 2015 Mar 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_12707.htm
Adults and children over 15 years: 1-2 table (400-800ьп). 4 times a day 1 hour after meals and in the evening before bed or if there is discomfort, epigastric pain, heartburn.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18362170
Bone marrow cells were cultured for 9 d in dendritic cells (DC) culture medium (DC-CM; RPMI 1640 containing GlutaMAX-I; Invitrogen) supplemented with 5% (vol/vol) FCS (Sigma-Aldrich), 50 μ M 2-mercaptoethanol (Sigma-Aldrich), 50 μ g/ml gentamicin (Invitrogen), and 20 ng/ml recombinant mouse GM-CSF (a gift from K. Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). 16 h before harvesting, DCs were exposed either to 10 μ g/ml of OVA, alum (Algeldrate), or OVA-alum suspension.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:39:35 GMT 2023
by
admin
on
Fri Dec 15 15:39:35 GMT 2023
|
Record UNII |
5QB0T2IUN0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 311.15
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
||
|
NCI_THESAURUS |
C2554
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
||
|
WHO-VATC |
QA02AB01
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
||
|
WHO-ATC |
A02AB01
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
||
|
DSLD |
2985 (Number of products:2)
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB33625
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
10176082
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
21645-51-2
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
DB06723
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
m1608
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
612
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
ALTERNATIVE | |||
|
33130
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
8012-63-3
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
SUPERSEDED | |||
|
1305556
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
ALTERNATIVE | |||
|
CHEMBL1200706
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL2109018
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
5QB0T2IUN0
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
SUB12826MIG
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
D000536
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
C39707
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
81948
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
1017502
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
100000127543
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
ALUMINUM HYDROXIDE
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | Description: A white, fine, amorphous powder; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS and sodium hydroxide (~80 g/l) TS. Category: Antacid. Storage: Aluminium hydroxide should be kept in a tightly closed container. Definition: Aluminium hydroxide contains not less than 71.9% and not more than 94.9% of Al(OH)3. | ||
|
ALUMINIUM HYDROXIDE
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
SUB32081
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
244-492-7
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY | |||
|
5QB0T2IUN0
Created by
admin on Fri Dec 15 15:39:35 GMT 2023 , Edited by admin on Fri Dec 15 15:39:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|